NURO VS CYCC Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend

Performance

NURO
10/100

NURO returned -70.24% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

CYCC
10/100

CYCC returned -69.77% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

NURO
63/100

2 analysts offer 12-month price targets for NURO. Together, they have an average target of 0, the most optimistic target put NURO at 0 within 12-months and the most pessimistic has NURO at 0.

CYCC
75/100

1 analysts offer 12-month price targets for CYCC. Together, they have an average target of 0, the most optimistic target put CYCC at 0 within 12-months and the most pessimistic has CYCC at 0.

Technicals

NURO
36/100

NURO receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

CYCC
14/100

CYCC receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

NURO
100/100

NURO has missed earnings 0 times in the last 20 quarters.

CYCC
10/100

CYCC has missed earnings 8 times in the last 20 quarters.

Profit

NURO
10/100

Out of the last 20 quarters, NURO has had 1 profitable quarters and has increased their profits year over year on 0 of them.

CYCC
10/100

Out of the last 20 quarters, CYCC has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

NURO
51/100

NURO has had a higher than average amount of volatility over the last 12 months giving it a score of 50 of 100.

CYCC
48/100

CYCC has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

Dividend

NURO

"Dividend" not found for NURO

CYCC
10/100

CYCC's most recent dividend was $0.08 per share, based on a share price of $0.34. It was a payout ratio of -2.36% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

NeuroMetrix, Inc. Common Stock Summary

Nasdaq / NURO
Healthcare
Medical - Devices
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Cyclacel Pharmaceuticals, Inc Summary

Nasdaq / CYCC
Healthcare
Biotechnology
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.